MDLN·Medline Inc.

On Nov 5, Medline Inc. announced that it had raised its full‑year organic sales guidance for 2026 to 10 %‑10.5 % for the third consecutive quarter, citing confidence in demand for its medical supplies and equipment. The company also warned that inflationary pressures and significant capital expenditures on quality initiatives could limit EBITDA growth in 2027 and potentially compress future margins. On Nov 4, Medline reported that net sales for the third quarter of 2026 rose 10.4 % to $7.9 billion, driven by new customer implementations and existing customer growth, while adjusted EBITDA increased 11.8 % to $1.0 billion, aided by tariff refunds. That same day, the company announced a $1 billion share buyback program, underscoring its confidence in its financial position. Also on Nov 4, Medline disclosed a layoff of 304 employees, primarily in corporate roles, as part of a broader simplification effort aimed at improving operational efficiency; the company noted an 11 % rise in net sales over the nine months ended September 26 but a 29 % decline in net income year‑over‑year, indicating financial strain. Finally, on Nov 4, Medline’s Q3 earnings included a net income of $195 million, with earnings per share of 22 cents and adjusted earnings of 44 cents per share, both surpassing Wall Street estimates.